StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Vir Biotechnology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Vir Biotechnology's operating cash flow for the twelve months ending Jun 30, 2026 was -$202.51M. For fiscal 2025 it was -$391.78M. The highest annual figure on record is $1.66B in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$391.78M–
FY2024Dec 31, 2024-$446.35M–
FY2023Dec 31, 2023-$778.79M-146.8%
FY2022Dec 31, 2022$1.66B–
FY2021Dec 31, 2021-$47.59M–
FY2020Dec 31, 2020-$190.94M–
FY2019Dec 31, 2019-$129.63M–
FY2018Dec 31, 2018-$94.10M–
FY2017Dec 31, 2017-$66.38M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$123.33M–
Q1 FY2026Mar 31, 2026-$132.39M–
Q4 FY2025Dec 31, 2025-$25.88M–
Q3 FY2025Sep 30, 2025-$167.57M–
Q2 FY2025Jun 30, 2025-$120.22M–
Q1 FY2025Mar 31, 2025-$78.12M–
Q4 FY2024Dec 31, 2024-$87.64M–
Q3 FY2024Sep 30, 2024-$171.48M–
Q2 FY2024Jun 30, 2024-$77.85M–
Q1 FY2024Mar 31, 2024-$109.39M–
Q4 FY2023Dec 31, 2023-$107.93M-407.3%
Q3 FY2023Sep 30, 2023-$155.83M-232.2%
Q2 FY2023Jun 30, 2023-$389.25M-140.5%
Q1 FY2023Mar 31, 2023-$125.78M-122.9%
Q4 FY2022Dec 31, 2022$35.13M+356.5%
Q3 FY2022Sep 30, 2022$117.90M–
Q2 FY2022Jun 30, 2022$960.14M+585.5%
Q1 FY2022Mar 31, 2022$550.09M–
Q4 FY2021Dec 31, 2021$7.70M–
Q3 FY2021Sep 30, 2021-$105.81M–
Q2 FY2021Jun 30, 2021$140.06M–
Q1 FY2021Mar 31, 2021-$89.53M–
Q4 FY2020Dec 31, 2020-$82.05M–
Q3 FY2020Sep 30, 2020-$49.84M–
Q2 FY2020Jun 30, 2020-$10.64M–
Q1 FY2020Mar 31, 2020-$48.41M–
Q4 FY2019Dec 31, 2019-$38.89M–
Q3 FY2019Sep 30, 2019-$36.96M–
Q2 FY2019Jun 30, 2019-$24.30M–
Q1 FY2019Mar 31, 2019-$29.49M–
Q4 FY2018Dec 31, 2018-$29.51M–

More Vir Biotechnology figures

See a number that looks wrong?